BRCA1 and peritoneal carcinoma: This includes BRCA1/2-mutated metastatic pancreatic cancer in 2019 [65], fallopian and primary peritoneal carcinoma in a combinational intervention with bevacizumab [66] and HR-deficient metastatic castration-resistant prostate cancer in 2020 [67].